Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why
01:14pm, Friday, 08'th Nov 2024
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside – Here's Why
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
09:50am, Thursday, 07'th Nov 2024
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.58 per share a year ago.
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update
07:30am, Thursday, 07'th Nov 2024
LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
09:47am, Tuesday, 05'th Nov 2024
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation
ADC Therapeutics to Present at November Investor Conferences
07:15am, Monday, 04'th Nov 2024
LAUSANNE, Switzerland , Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced pa
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Friday, 01'st Nov 2024
LAUSANNE, Switzerland , Nov. 1, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 01'st Nov 2024
Here is how ADC Therapeutics SA (ADCT) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
07:15am, Thursday, 31'st Oct 2024
LAUSANNE, Switzerland , Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Tuesday, 01'st Oct 2024
LAUSANNE, Switzerland, Oct. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Tuesday, 03'rd Sep 2024
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announce
ADC Therapeutics to Present at Upcoming Investor Conferences
07:15am, Tuesday, 03'rd Sep 2024
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announce
ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript
09:26am, Sunday, 11'th Aug 2024
Start Time: 08:30 January 1, 0000 9:04 AM ET ADC Therapeutics SA (NYSE:ADCT ) Q2 2024 Earnings Conference Call August 06, 2024, 08:30 AM ET Company Participants Ameet Mallik - CEO Jose Carmona - CFO M
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
09:40am, Tuesday, 06'th Aug 2024
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.58 per share a year ago.
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
07:30am, Tuesday, 06'th Aug 2024
ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Thursday, 01'st Aug 2024
LAUSANNE, Switzerland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced
